330 related articles for article (PubMed ID: 9714974)
21. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study.
Syed TA; Khayyami M; Kriz D; Svanberg K; Kahlon RC; Ahmad SA; Ahmad SA
J Mol Med (Berl); 1995 May; 73(5):255-8. PubMed ID: 7670929
[TBL] [Abstract][Full Text] [Related]
22. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream.
Schaen L; Mercurio MG
Pediatr Dermatol; 2001; 18(5):450-2. PubMed ID: 11737697
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation].
Vexiau D; Decuypère L; Moyse D; Aractingi S
Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):845-51. PubMed ID: 16327713
[TBL] [Abstract][Full Text] [Related]
24. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women.
Garland SM; Waddell R; Mindel A; Denham IM; McCloskey JC
Int J STD AIDS; 2006 Jul; 17(7):448-52. PubMed ID: 16820073
[TBL] [Abstract][Full Text] [Related]
25. Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males.
Maw RD; Kinghorn GR; Bowman CA; Goh BT; Nayagam AT; Nathan M
J Eur Acad Dermatol Venereol; 2002 Jan; 16(1):58-62. PubMed ID: 11952292
[TBL] [Abstract][Full Text] [Related]
26. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
Saiag P; Bauhofer A; Bouscarat F; Aquilina C; Ortonne JP; Dupin N; Mougin C
Br J Dermatol; 2009 Oct; 161(4):904-9. PubMed ID: 19466962
[TBL] [Abstract][Full Text] [Related]
27. [Topical imiquimod cream in the treatment of external anogenital warts: personal experience].
Senatori R; Dionisi B; Lippa P; Inghirami P
Minerva Ginecol; 2003 Dec; 55(6):541-6. PubMed ID: 14676745
[TBL] [Abstract][Full Text] [Related]
28. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study.
Syed TA; Lundin S; Ahmad SA
Dermatology; 1994; 189(2):142-5. PubMed ID: 8075441
[TBL] [Abstract][Full Text] [Related]
29. Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial.
Kumar P; Dar L; Saldiwal S; Varma S; Datt Upadhyay A; Talwar D; Sharma VK; Verma KK; Dwivedi SN; Raj R; Gupta S
JAMA Dermatol; 2014 Oct; 150(10):1072-8. PubMed ID: 25103148
[TBL] [Abstract][Full Text] [Related]
30. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study.
Syed TA; Cheema KM; Khayyami M; Ahmad SA; Ahmad SH; Ahmad S; Ahmad SA
Dermatology; 1995; 191(2):129-32. PubMed ID: 8520059
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta JJ; Correa LA; He Q; Wolff JC
J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1054-60. PubMed ID: 17714124
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic approaches to genital warts.
Beutner KR; Ferenczy A
Am J Med; 1997 May; 102(5A):28-37. PubMed ID: 9217660
[TBL] [Abstract][Full Text] [Related]
33. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group.
Gilson RJ; Shupack JL; Friedman-Kien AE; Conant MA; Weber JN; Nayagam AT; Swann RV; Pietig DC; Smith MH; Owens ML
AIDS; 1999 Dec; 13(17):2397-404. PubMed ID: 10597781
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children.
Grussendorf-Conen EI; Jacobs S
Pediatr Dermatol; 2002; 19(3):263-6. PubMed ID: 12047649
[TBL] [Abstract][Full Text] [Related]
35. [Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)].
Protasov AD; Lipatov IS; Kostinov MP; Tezikov YV; Shmitko AD; Pakhomov DV; Blagovidov DA; Zhestkov AV; Ryzhov AA; Vekhova EV
Urologiia; 2016 Nov; (5):47-51. PubMed ID: 28248020
[TBL] [Abstract][Full Text] [Related]
36. Imiquimod for the treatment of genital warts: a quantitative systematic review.
Moore RA; Edwards JE; Hopwood J; Hicks D
BMC Infect Dis; 2001; 1():3. PubMed ID: 11401728
[TBL] [Abstract][Full Text] [Related]
37. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
Hoyme UB; Hagedorn M; Schindler AE; Schneede P; Hopfenmüller W; Schorn K; Eul A
Infect Dis Obstet Gynecol; 2002; 10(2):79-88. PubMed ID: 12530484
[TBL] [Abstract][Full Text] [Related]
38. Imiquimod: a review.
Gupta AK; Browne M; Bluhm R
J Cutan Med Surg; 2002; 6(6):554-60. PubMed ID: 12362256
[TBL] [Abstract][Full Text] [Related]
39. Extensive condyloma acuminata treated with imiquimod 5% cream: a case report.
Cox JT
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():51-4. PubMed ID: 14616817
[TBL] [Abstract][Full Text] [Related]
40. Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study.
Syed TA; Ahmadpour OA
Int J STD AIDS; 1998 Dec; 9(12):769-72. PubMed ID: 9874127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]